β-catenin activates TGF-β-induced epithelial-mesenchymal transition in adenomyosis.
Jung-Yoon YooBon Jeong KuTae Hoon KimJong Il AhnJi Yeon AhnWoo Sub YangJeong Mook LimMaketo M TaketoJung-Ho ShinJae-Wook JeongPublished in: Experimental & molecular medicine (2020)
Adenomyosis is defined as the presence of ectopic nests of endometrial glands and stroma within the myometrium. Adenomyosis is a common cause of dysmenorrhea, menorrhagia, and chronic pelvic pain but is often underdiagnosed. Despite its prevalence and severity of symptoms, its pathogenesis and etiology are poorly understood. Our previous study showed that aberrant activation of β-catenin results in adenomyosis through epithelial-mesenchymal transition. Using transcriptomic and ChIP-seq analysis, we identified activation of TGF-β signaling in the uteri of mutant mice that expressed dominant stabilized β-catenin in the uterus. There was a strong positive correlation between β-catenin and TGF-β2 proteins in women with adenomyosis. Furthermore, treatment with pirfenidone, a TGF-β inhibitor, increased E-cadherin expression and reduced cell invasiveness in Ishikawa cells with nuclear β-catenin. Our results suggest that β-catenin activates TGF-β-induced epithelial-mesenchymal transition in adenomyosis. This finding describes the molecular pathogenesis of adenomyosis and the use of TGF-β as a potential therapeutic target for adenomyosis.
Keyphrases
- epithelial mesenchymal transition
- transforming growth factor
- signaling pathway
- single cell
- high glucose
- poor prognosis
- cell proliferation
- risk factors
- type diabetes
- rna seq
- chronic pain
- idiopathic pulmonary fibrosis
- metabolic syndrome
- physical activity
- gene expression
- cell death
- pain management
- spinal cord
- insulin resistance
- climate change
- cell therapy
- dna methylation
- sleep quality
- single molecule
- replacement therapy